In an effort to guarantee that generic versions of abuse-deterrent formulation (ADF) opioids are as safe and effective as their approved, brand-name ADF counterparts, the FDA has issued a draft guidance for the pharmaceutical industry to follow as these drugs enter development. At least one pain medicine expert, however, is confused by the ultimate goals of the endeavor.
“Collaboration is critical in fostering innovation in the field of abuse deterrence,” said Douglas